US · RVTY
Revvity, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Waltham, MA 02451
- Website
- perkinelmer.com
Price · as of 2025-12-28
$86.68
Market cap 11.15B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $101.32 | +16.89% |
| Intrinsic Value(DCF) | $39.79 | -54.1% |
| Graham-Dodd Method(GD) | $11.95 | -86.21% |
| Graham Formula(GF) | $24.71 | -71.5% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $25.21 | $39.72 | $0.16 | $0.00 | $0.21 |
| 2012 | $33.83 | $51.14 | $0.00 | $0.00 | $10.65 |
| 2013 | $43.95 | $48.05 | $0.00 | $1.93 | $15.60 |
| 2014 | $45.79 | $50.18 | $0.00 | $0.66 | $15.71 |
| 2015 | $47.27 | $53.35 | $0.61 | $4.11 | $4.52 |
| 2016 | $54.23 | $60.83 | $1.75 | $5.59 | $18.58 |
| 2017 | $77.61 | $69.22 | $4.20 | $0.00 | $14.86 |
| 2018 | $90.31 | $77.03 | $0.00 | $3.27 | $65.08 |
| 2019 | $82.34 | $70.72 | $0.00 | $3.38 | $24.16 |
| 2020 | $121.69 | $109.19 | $150.20 | $31.03 | $247.94 |
| 2021 | $164.28 | $176.12 | $33.70 | $40.84 | $75.33 |
| 2022 | $119.30 | $115.58 | $0.27 | $25.50 | $0.00 |
| 2023 | $108.75 | $99.90 | $13.93 | $1.79 | $7.72 |
| 2024 | $117.23 | $108.66 | $10.76 | $17.64 | $20.05 |
| 2025 | $95.59 | $101.32 | $6.57 | $11.95 | $24.71 |
AI valuation
Our deep-learning model estimates Revvity, Inc.'s (RVTY) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $101.32
- Current price
- $86.68
- AI upside
- +16.89%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$39.79
-54.1% upside
Graham-Dodd
$11.95
-86.21% upside
Graham Formula
$24.71
-71.5% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| RVTY | Revvity, Inc. | $86.68 | 11.15B | +17% | -54% | -86% | -71% | 44.87 | 1.49 | 3.79 | 20.25 | — | -6.33 | 53.08% | 12.49% | 8.46% | 3.23% | 3.28% | 1.96% | 0.48 | 3.87 | 1.68 | 1.25 | 3.92 | -1369.00% | 367.00% | -617.00% | 4.70% | 0.44 | 5.17% | 0.30% | 13.60% | 7.89% | 37.63 | 26.40 | 4.70 | 1.74 |
| ALGN | Align Technology, Inc. | $190.10 | 13.64B | +1% | -52% | -59% | -74% | 33.42 | 3.39 | 3.40 | 15.94 | 6259.75 | 3.96 | 68.33% | 15.27% | 10.17% | 10.39% | 14.49% | 6.59% | 0.02 | — | 1.36 | 1.14 | -1.27 | 53.00% | 90.00% | -473.00% | 4.33% | 0.31 | 19.89% | 0.00% | 0.00% | 0.64% | 20.61 | 21.41 | 3.15 | 4.87 |
| CRL | Charles River Laboratorie… | $178.49 | 8.78B | -31% | -60% | — | — | -62.27 | 2.80 | 2.20 | 12.85 | — | 146.61 | 30.52% | 12.65% | -3.59% | -4.29% | 8.46% | -1.94% | 0.97 | 4.74 | 1.29 | 0.82 | 3.13 | -155500.00% | -85.00% | 337.00% | 5.86% | 0.66 | 8.64% | 0.00% | 0.00% | 4.07% | 23.05 | 22.57 | 2.91 | 2.48 |
| ENSG | The Ensign Group, Inc. | $214.17 | 12.45B | -38% | +33% | -70% | -27% | 35.93 | 5.54 | 2.45 | 28.09 | 255.48 | 5.81 | 13.74% | 8.58% | 6.80% | 16.92% | 7.20% | 6.80% | 1.86 | 54.31 | 1.42 | 1.35 | 6.43 | 1406.00% | 1872.00% | 9620.00% | 3.00% | 0.63 | 8.15% | 0.12% | 4.20% | 0.29% | 36.77 | 43.03 | 3.15 | 4.02 |
| EXAS | Exact Sciences Corporatio… | $103.38 | 19.73B | -34% | -59% | — | — | -93.78 | 8.12 | 6.01 | 171.91 | — | -21.99 | 69.69% | -3.05% | -6.40% | -8.66% | -2.45% | -3.53% | 1.05 | -3.01 | 2.43 | 1.97 | 12.79 | -8032.00% | 1769.00% | 37860.00% | 1.83% | 0.77 | 8.83% | 0.00% | 0.00% | 3.01% | -212.55 | 59.02 | 6.49 | 2.94 |
| GH | Guardant Health, Inc. | $93.90 | 12.32B | -39% | -48% | — | — | -27.78 | -116.44 | 11.77 | -32.21 | — | -57.11 | 64.46% | -44.43% | -42.39% | 348.42% | -117.88% | -23.79% | -16.94 | -111.96 | 4.84 | 4.42 | -3.49 | -674.00% | 3288.00% | -1523.00% | -2.02% | -0.61 | -63.16% | 0.00% | 0.00% | 0.12% | -27.61 | -51.68 | 12.26 | 1.67 |
| HIMS | Hims & Hers Health, Inc. | $14.52 | 3.19B | +579% | +6,822% | -72% | +154% | 28.88 | 6.85 | 1.58 | 24.62 | — | 55.76 | 59.31% | 5.18% | 5.47% | 25.23% | 17.20% | 8.97% | 2.34 | — | 1.90 | 1.51 | 5.80 | -377.00% | 5900.00% | -6271.00% | 1.99% | 0.74 | 10.45% | 0.00% | 0.00% | 2.43% | 36.11 | 59.40 | 1.87 | 2.78 |
| ICLR | ICON Public Limited Compa… | $108.14 | 8.26B | +89% | -31% | -50% | -11% | 19.44 | 1.62 | 1.86 | 11.80 | 67.55 | -4.98 | 29.42% | 13.26% | 9.56% | 8.44% | 7.88% | 4.67% | 0.38 | 4.63 | 1.26 | 1.21 | 1.96 | 2878.00% | 199.00% | 963.00% | 7.27% | 0.46 | 8.81% | 0.00% | 0.00% | 6.47% | 16.81 | 16.50 | 2.23 | 2.24 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| RDY | Dr. Reddy's Laboratories … | $14.38 | 11.97B | -27% | +23% | -53% | +28% | 19.94 | 3.42 | 3.51 | 11.69 | 1373.07 | 5.08 | 58.50% | 22.07% | 17.37% | 18.65% | 19.79% | 13.00% | 0.14 | 25.40 | 1.92 | 1.29 | 0.33 | 145.00% | 1661.00% | -3316.00% | 1.05% | 0.36 | 4.44% | 0.58% | 11.60% | 0.71% | 15.73 | 93.95 | 3.47 | 6.72 |
| SOLV | Solventum Corporation | $74.20 | 12.87B | +72% | -56% | -45% | +7% | 8.17 | 2.52 | 1.53 | 6.62 | 3.68 | -3.91 | 53.47% | 26.20% | 18.69% | 38.86% | 20.41% | 10.82% | 1.00 | 6.29 | 1.23 | 0.61 | 1.63 | 22174.00% | 86.00% | -10124.00% | -0.08% | 0.12 | -0.10% | 0.00% | 0.00% | 24.32% | 7.73 | -1686.63 | 2.03 | 2.15 |
About Revvity, Inc.
Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets worldwide. It operates through two segments, Discovery & Analytical Solutions and Diagnostics. The Discovery & Analytical Solutions segment provides instruments, reagents, informatics, software, subscriptions, detection, and imaging technologies that enable scientists to enhance research breakthroughs in the life sciences research market, as well as contract research and laboratory services. It also provides analytical technologies, solutions, and services for its customers to understand the characterize the health of various aspects, including air, water, and soil. In addition, this segment offers solutions to farmers and food producers; and analytical instrumentation for the industrial market, which includes the chemical, semiconductor and electronics, energy, lubricant, petrochemical, and polymer industries. The Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This segment also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.
- CEO
- Prahlad R. Singh
- Employees
- 11K
- Beta
- 1.09
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($39.79 ÷ $86.68) − 1 = -54.1% (DCF, example).